[go: up one dir, main page]

PE20090596A1 - Imidazoles biciclicos fusionados - Google Patents

Imidazoles biciclicos fusionados

Info

Publication number
PE20090596A1
PE20090596A1 PE2008001379A PE2008001379A PE20090596A1 PE 20090596 A1 PE20090596 A1 PE 20090596A1 PE 2008001379 A PE2008001379 A PE 2008001379A PE 2008001379 A PE2008001379 A PE 2008001379A PE 20090596 A1 PE20090596 A1 PE 20090596A1
Authority
PE
Peru
Prior art keywords
phenyl
alkyl
imidazo
triazol
piperidin
Prior art date
Application number
PE2008001379A
Other languages
English (en)
Inventor
Swen Ulfried Karl Raimund Holder
Armin Zulch
Thomas Bar
Thomas Maier
Astrid Zimmermann
Thomas Beckers
Volker Gekeler
Hemant Joshi
Yogesh Munot
Umesh Bhise
Sunil Chavan
Sachin Shivatare
Sarvesh Patel
Vikas Gore
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07118733A external-priority patent/EP2062893A1/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20090596A1 publication Critical patent/PE20090596A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

REFERIDA A COMPUESTOS DERIVADOS DE IMIDAZOLES BICICLICOS FUSIONADOS DE FORMULA (I) DONDE EL ANILLO B Y EL IMIDAZOL AL CUAL ESTA FUSIONADO FORMAN (a), (b), (c), ENTRE OTROS, EN DONDE R1 ES H, ALQUILO(C1-C4), HALOGENO, AMINO, -CF3, -CN, ENTRE OTROS; R3 ES H, ALQUILO(C1-C4) O HALOGENO; R4 ES FENILO NO SUSTITUIDO, PIRIDINILO, OXAZOLILO, ENTRE OTROS; R6 ES H O ALQUILO(C1-C4); R7 ES -W-Y, DONDE W ES HETEROARILENO MONOCICLICO DE 5 MIEMBROS OPCIONALMENTE SUSTITUIDO CON R8, EN DONDE R8 ES ALQUILO(C1-C4) O CICLOALQUILO(C3-C7); Y ES FENILO O HETEROARILO MONOCICLICO DE 5 O 6 MIEMBROS OPCIONALMENTE SUSTITUIDO CON R9, EN DONDE R9 ES ALQUILO(C1-C4), ALCOXI(C1-C4) O HALOGENO. SON COMPUESTOS PREFERIDOS: 3-FENIL-2-(4-{[4-(5-PIRIDIN-2-IL-1,2,4-TRIAZOL-3-IL)PIPERIDIN-1-IL]METIL}FENIL)IMIDAZO[1,2-a]PIRIMIDINA, 3-FENIL-2-(4-{[4-(5-PIRIDIN-2-IL-1H-1,2,4-TRIAZOL-3-IL)PIPERIDIN-1-IL]METIL}FENIL)IMIDAZO[1,2-a]PIRIDINA, 7-FENIL-6-(4-{[4-(5-PIRIDIN-2-IL-1H-1,2,4-TRIAZOL-3-IL)PIPERIDIN-1-IL]METIL}FENIL)IMIDAZO[1,2-b][1,2,4]TRIAZINA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA QUINASA AKt SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES HIPERPROLIFERATIVAS TALES COMO NEOPLASIAS BENIGNAS O MALIGNAS
PE2008001379A 2007-08-14 2008-08-14 Imidazoles biciclicos fusionados PE20090596A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1573MU2007 2007-08-14
EP07118733A EP2062893A1 (en) 2007-10-18 2007-10-18 Fused imidazoles for cancer treatment

Publications (1)

Publication Number Publication Date
PE20090596A1 true PE20090596A1 (es) 2009-06-07

Family

ID=39876840

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001379A PE20090596A1 (es) 2007-08-14 2008-08-14 Imidazoles biciclicos fusionados

Country Status (24)

Country Link
US (2) US8592591B2 (es)
EP (1) EP2176259B1 (es)
JP (1) JP5327652B2 (es)
KR (1) KR20100049589A (es)
CN (1) CN101835776A (es)
AR (1) AR067946A1 (es)
AT (1) ATE503757T1 (es)
AU (1) AU2008288390A1 (es)
CA (1) CA2695251C (es)
CL (1) CL2008002397A1 (es)
CR (1) CR11271A (es)
DE (1) DE602008005894D1 (es)
DO (1) DOP2010000057A (es)
EA (1) EA201000297A1 (es)
EC (1) ECSP109965A (es)
MA (1) MA31609B1 (es)
MX (1) MX2010001745A (es)
PA (1) PA8793301A1 (es)
PE (1) PE20090596A1 (es)
SV (1) SV2010003482A (es)
TN (1) TN2010000071A1 (es)
TW (1) TW200924761A (es)
UY (1) UY31292A1 (es)
WO (1) WO2009021990A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573357B (zh) * 2006-10-19 2013-01-23 武田药品工业株式会社 吲哚化合物
PE20090596A1 (es) * 2007-08-14 2009-06-07 Bayer Schering Pharma Ag Imidazoles biciclicos fusionados
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
EP2252293B1 (en) 2008-03-14 2018-06-27 Intellikine, LLC Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
AU2009268611B2 (en) 2008-07-08 2015-04-09 Intellikine, Llc Kinase inhibitors and methods of use
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
JP5667085B2 (ja) * 2009-02-13 2015-02-12 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Ａｋｔインヒビターとしての融合されたピリミジン
AU2010226490A1 (en) 2009-03-20 2011-10-06 Amgen Inc. Inhibitors of PI3 kinase
WO2010125799A1 (ja) 2009-04-27 2010-11-04 塩野義製薬株式会社 Pi3k阻害活性を有するウレア誘導体
AU2010284254B2 (en) 2009-08-17 2015-09-17 Intellikine, Llc Heterocyclic compounds and uses thereof
CA2778949C (en) 2009-10-30 2018-02-27 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as pde10 inhibitors
CA2778265A1 (en) * 2009-11-02 2011-05-05 Abbott Laboratories Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition
US9073927B2 (en) 2010-01-22 2015-07-07 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Inhibitors of PI3 kinase
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
EP2593451B1 (en) * 2010-07-12 2015-08-19 Bayer Intellectual Property GmbH Substituted imidazo[1,2-a]pyrimidines and -pyridines
CA2806655A1 (en) 2010-07-28 2012-02-02 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-b]pyridazines
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
DE102011008352A1 (de) * 2011-01-12 2012-07-12 Merck Patent Gmbh 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate
CA2828483A1 (en) 2011-02-23 2012-11-01 Intellikine, Llc Combination of kinase inhibitors and uses thereof
US8772283B2 (en) 2011-04-06 2014-07-08 Taiho Pharmaceutical Co., Ltd. Imidazo-oxazine compound or salt thereof
US9206185B2 (en) * 2011-04-07 2015-12-08 Bayer Intellectual Property Gmbh Imidazopyridazines as Akt kinase inhibitors
AU2012277912B2 (en) 2011-06-27 2017-03-23 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
CA2860724A1 (en) 2012-01-10 2013-07-18 Bayer Intellectual Property Gmbh Substituted pyrazolopyrimidines as akt kinase inhibitors
CA2860723A1 (en) * 2012-01-10 2013-07-18 Bayer Intellectual Property Gmbh Substituted imidazopyrazines as akt kinase inhibitors
CA2872216C (en) 2012-06-26 2021-07-20 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
ES2660215T3 (es) * 2012-07-02 2018-03-21 Taiho Pharmaceutical Co., Ltd. Potenciador de efecto antitumoral que comprende un compuesto de imidazooxazina
CN104411314B (zh) 2012-07-09 2017-10-20 詹森药业有限公司 磷酸二酯酶10的抑制剂
JP6360881B2 (ja) 2013-03-22 2018-07-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 触媒的ｍｔｏｒｃ１／２阻害薬及びオーロラａキナーゼの選択的阻害薬の組合せ
GB201321732D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
CN107428779A (zh) 2015-02-27 2017-12-01 大鹏药品工业株式会社 咪唑并噁嗪晶体、含有所述晶体的药物组合物和制备所述晶体的方法
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
CN110099898B (zh) * 2016-10-24 2023-07-25 优曼尼蒂治疗公司 化合物及其用途
WO2018129403A1 (en) 2017-01-06 2018-07-12 Yumanity Therapeutics Methods for the treatment of neurological disorders
EP3700934A4 (en) 2017-10-24 2021-10-27 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
CN112312913B (zh) 2018-03-23 2024-03-08 詹森药业有限公司 化合物和其用途
CA3102279A1 (en) 2018-06-01 2019-12-05 Cornell University Combination therapy for pi3k-associated disease or disorder
AU2020212034A1 (en) 2019-01-24 2021-09-16 Janssen Pharmaceutica Nv Compounds and uses thereof
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
CN118812530A (zh) * 2023-04-18 2024-10-22 中国科学院大连化学物理研究所 一种Pd/C双组分体系催化木质素及模型化合物制备咪唑吡啶类化合物的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001249679A1 (en) * 2000-03-31 2001-10-15 Ortho-Mcneil Pharmaceutical, Inc. Phenyl-substituted imidazopyridines
CA2407573C (en) * 2000-04-27 2011-09-13 Yamanouchi Pharmaceutical Co. Ltd. Imidazopyridine derivatives
AU2004233828B2 (en) 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
DE602004010680T2 (de) * 2003-07-30 2009-01-02 Laboratorios S.A.L.V.A.T., S.A., Esplugues De Llobregat Substituierte imidazopyrimidine zur prävention und behandlung von krebs
US7655649B2 (en) 2004-04-09 2010-02-02 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
EP1784175A4 (en) * 2004-08-23 2009-07-22 Merck & Co Inc INHIBITORS OF ACT ACTIVITY
AU2005316826A1 (en) * 2004-12-15 2006-06-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
WO2006125101A2 (en) 2005-05-20 2006-11-23 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
WO2007028051A2 (en) * 2005-09-02 2007-03-08 Abbott Laboratories Novel imidazo based heterocycles
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US7530313B2 (en) 2006-05-12 2009-05-12 Day & Zimmerman, Inc. Self-destruct fuze delay mechanism
PE20090596A1 (es) * 2007-08-14 2009-06-07 Bayer Schering Pharma Ag Imidazoles biciclicos fusionados

Also Published As

Publication number Publication date
MA31609B1 (fr) 2010-08-02
CR11271A (es) 2010-05-19
EP2176259B1 (en) 2011-03-30
EA201000297A1 (ru) 2010-08-30
WO2009021990A1 (en) 2009-02-19
AR067946A1 (es) 2009-10-28
US8592591B2 (en) 2013-11-26
PA8793301A1 (es) 2009-04-23
US9387204B2 (en) 2016-07-12
UY31292A1 (es) 2009-03-31
TW200924761A (en) 2009-06-16
MX2010001745A (es) 2010-03-10
US20140088110A1 (en) 2014-03-27
SV2010003482A (es) 2010-07-06
KR20100049589A (ko) 2010-05-12
AU2008288390A1 (en) 2009-02-19
CL2008002397A1 (es) 2009-09-25
DOP2010000057A (es) 2010-04-15
EP2176259A1 (en) 2010-04-21
DE602008005894D1 (de) 2011-05-12
CA2695251A1 (en) 2009-02-19
US20090156604A1 (en) 2009-06-18
JP5327652B2 (ja) 2013-10-30
ECSP109965A (es) 2010-03-31
CN101835776A (zh) 2010-09-15
TN2010000071A1 (en) 2011-09-26
CA2695251C (en) 2016-06-21
JP2010535847A (ja) 2010-11-25
ATE503757T1 (de) 2011-04-15

Similar Documents

Publication Publication Date Title
PE20090596A1 (es) Imidazoles biciclicos fusionados
PE20120534A1 (es) PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt
PE20090944A1 (es) PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT
PE20090511A1 (es) Imidazopiridinonas
PE20130306A1 (es) Morfolinopirimidinas y su uso en terapia
RU2018123779A (ru) Новые соединения
PE20110991A1 (es) Compuestos de fenil-piridazinona-pirazol-fenilo como inhibidores de pde
PE20091833A1 (es) Derivados heterociclicos espiro biciclicos o heterociclicos biciclicos, puenteados, de pirazolo [1,5-a]pirimidinas como inhibidores de quinasas raf y metodos para su preparacion
AR082799A1 (es) Derivados de quinolina y quinoxalina como inhibidores de quinasa
PE20091493A1 (es) Inhibidores de quinasa de pirrolopirazina
NZ626394A (en) Substituted annulated pyrimidines and triazines, and use thereof
PE20140234A1 (es) Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1
JP2017125037A (ja) イミダゾピロリジノン化合物
PE20090674A1 (es) Compuestos multiciclicos
PE20110328A1 (es) Compuestos heterociclicos fusionados como moduladores del receptor de la orexina
PE20091468A1 (es) DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
JP2013542982A5 (es)
PE20080403A1 (es) Derivados heterociclicos fusionados y metodos de uso
AR092955A1 (es) Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona
JP2014525432A5 (es)
NZ600430A (en) Spiro-oxindole mdm2 antagonists
PE20121025A1 (es) Compuestos de benzoxazepina como inhibidores de la p13k
PE20110411A1 (es) Imidazopiridazinacarbonitrilos como inhibidores de quinasa
PE20130650A1 (es) Derivados de tetrahidro-pirido-pirimidina

Legal Events

Date Code Title Description
FC Refusal